Fundamental Analysis of ENLIVEN THERAPEUTICS INC(NASDAQ:ELVN) stock

Fundamental Rating

Taking everything into account, ELVN scores 3 out of 10 in our fundamental rating. ELVN was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability. ELVN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ELVN had negative earnings in the past year.

In the past year ELVN has reported a negative cash flow from operations.

ELVN had negative earnings in 4 of the past 5 years.

In the past 5 years ELVN always reported negative operating cash flow.

1.2 Ratios

ELVN has a Return On Assets (-26.33%) which is in line with its industry peers.

ELVN's Return On Equity of -29.11% is fine compared to the rest of the industry. ELVN outperforms 68.21% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.33%
ROE	-29.11%
ROIC	N/A

ROA(3y)-26.47%

ROA(5y)-40.81%

ROE(3y)-28.93%

ROE(5y)-45.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELVN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELVN has more shares outstanding

Compared to 5 years ago, ELVN has more shares outstanding

There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ELVN has an Altman-Z score of 18.45. This indicates that ELVN is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 18.45, ELVN belongs to the best of the industry, outperforming 91.79% of the companies in the same industry.

There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	18.45

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ELVN has a Current Ratio of 10.28. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.

ELVN has a Current ratio of 10.28. This is amongst the best in the industry. ELVN outperforms 87.18% of its industry peers.

A Quick Ratio of 10.28 indicates that ELVN has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 10.28, ELVN belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	10.28
Quick Ratio	10.28

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ELVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.10%, which is quite impressive.

EPS 1Y (TTM)47.1%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-109.74%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ELVN will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.93% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-12.95%

EPS Next 2Y-18.6%

EPS Next 3Y-12.93%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELVN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELVN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ELVN's earnings are expected to decrease with -12.93% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-18.6%

EPS Next 3Y-12.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ELVN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (4/29/2024, 7:00:01 PM)

After market: 17.65 -0.14 (-0.79%)

17.79

+0.61 (+3.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap830.79M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.33%
ROE	-29.11%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	10.28
Quick Ratio	10.28
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)47.1%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-12.95%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ENLIVEN THERAPEUTICS INC (ELVN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens